Stryker announced that its Pangea Systems including Femur, Fibula, Tibia, Humerus and Utility have received 510k clearance from the U.S. Food & Drug Administration. “FDA clearance is a critical milestone for our Pangea Systems,” said Eric Tamweber, Vice President and General Manager, Stryker’s Trauma business unit. “With these new systems, we are now offering surgeons a comprehensive portfolio that supports a wide range of their trauma needs.” Designed by the collaborative efforts of world-renowned orthopaedic surgeons, the Pangea plates offer an evidence-based design for implant fit. The system was designed to enhance plate fit and screw placement while elevating the plating market through anatomically contoured implants in patient populations with a wide variety of fracture patterns. The intuitive and streamlined instrumentation and implant trays will include 20 anatomic plates and 13 utility plates all accessible in one platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SYK:
- Stryker upgraded to Buy from Neutral at BofA
- Nvidia upgraded, CrowdStrike downgraded: Wall Street’s top analyst calls
- Zimmer Biomet upgraded to Buy from Neutral at BTIG
- Stryker to participate in the 2023 Wells Fargo Securities Healthcare Conference
- Early notable gainers among liquid option names on August 4th